Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non–Small-Cell Lung Cancer in Clinical Practice

Laurie E. Steffen McLouth, Thomas W. Lycan, Beverly J. Levine, Jennifer Gabbard, Jimmy Ruiz, Michael Farris, Stefan C. Grant, Nicholas M. Pajewski, Kathryn E. Weaver, W. Jeffrey Petty

Research output: Contribution to journalArticlepeer-review

31 Scopus citations

Abstract

The quality of life and symptom experience for metastatic lung cancer patients treated with immunotherapy or chemoimmunotherapy in routine care has not been described. In our survey of 60 metastatic lung cancer patients receiving these treatments, 20% to 40% reported moderate symptoms (eg, rash, muscle ache). Patient-reported outcomes need to be monitored in clinical practice, especially for patients with worse physical function.

Original languageEnglish
Pages (from-to)255-263.e4
JournalClinical Lung Cancer
Volume21
Issue number3
DOIs
StatePublished - May 2020

Bibliographical note

Publisher Copyright:
© 2019 Elsevier Inc.

Keywords

  • Atezolizumab
  • Health-related quality of life
  • Nivolumab
  • Pembrolizumab
  • Performance status

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint

Dive into the research topics of 'Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non–Small-Cell Lung Cancer in Clinical Practice'. Together they form a unique fingerprint.

Cite this